While There’s Lots of Discussion about COVID-19 Vaccine-based Myocarditis in the West, What About ADEs’ in the East?
https://trialsitenews.com/whil…t-about-ades-in-the-east/
As you know, antibody disease enhancement (ADE) was a major concern during the development of the Covid-19 vaccines. These concerns were well-founded and even the regulators were on record of being concerned and watching closely for any signals during the randomized controlled trials (RCTs). Luckily, those signals never presented. Many anti-vax viewpoints still bring up the risk of ADE in the newly developed vaccines despite the fact that there are no signals of it after hundreds of millions of doses being administered at least for the vaccines under EUA in the USA. But that doesn’t imply that the risk of ADE in Covid-19 vaccines is no longer present. In fact, there are concerning signs of it potentially playing out already. Luckily, the signs are isolated to the Chinese developed vaccines. Specifically of concern is data from Sinopharm’s inactivated vaccine, BBIBP-CorV.
A recent entry in Medical News Today elicited response and discussion among a valued member from the TrialSite Community. Now, the efficacy of this vaccine is questionable and the data from the trials was not up to the standards of the better respected International Regulatory agencies. Yet, that didn’t stop the WHO from recommending its use.
Sinopharm Market—How are Vaccine Beneficiaries Faring?
It’s long been clear that countries that deployed the Sinopharm vaccine as a major component of their vaccine campaigns haven’t seen the dramatic reduction in cases per capita as expected from nations using more efficacious vaccines such as Israel, the USA, and the UK.
This is now being questioned in the media and the approach to address the reduced efficacy is being developed in many of these countries i.e. booster with an mRNA vaccine, 3rd shot of Sinopharm etc. The narrative that’s typically been used when PHAs and MSM have covered this topic is that the vaccines are still providing reduced disease severity. However, the data doesn’t back up those assertions. The island nation of Seychelles in the Indian Ocean provides a very illustrative example of the Sinopharm vaccine’s lack of efficacy. Based on entries in OurWorldinData.org, we find that Seychelles is among the most highly vaccinated countries in the world at 140 vaccination shots per 100 people. In comparison, the US is at 96 vaccinations per 100 people. However, Seychelles is still experiencing an alarmingly high new average daily case rate of 1442/1Million compared to the US at 36/Million.
Questionable Sinopharm Evidence?
Now if Sinopharm was resulting in cases with the dramatically less severe disease, one might argue that the vaccine is still providing benefits despite the staggering high new case count. However, even more concerning, is that Seychelles is suffering one of the highest new deaths per capita in the world at 11.6/million. This compares to the US at
only .9/million. What is causing this frighteningly high death rate in one of the most vaccinated populations in the world? Many would say this is a concerning signal of ADE caused by the Sinopharm vaccine that should be investigated immediately.
What’s the Priority?
Strange how a tiny fraction of mostly benign AEs of myocarditis in mRNA vaccines draw a firestorm of global media attention but a shocking death rate in a highly vaccinated population using Sinopharm goes unnoticed.
Signs of this Sinopharm issue are being seen in other countries such as Chile and Bahrain. However, those countries used larger percentages of other vaccines in addition to Sinopharm. This masks the negative effects from Sinopharm and makes analysis difficult to isolate without granular data by vaccine type. This granular data is not easily
obtained. Of course, this is to some extent speculation as the actual data is difficult to access in its entirety.
Sinopharm Background
Based in China, the Sinopharm vaccine BIBP was developed by Sinopharm/China National Pharmaceutical Group. Their parent company is Singopharm Industry Investment, according to an entry in Wikipedia a 51-49 joint venture of China state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its shares were listed on the Hong Kong Stock Exchange in 2009.